Latest News about ASND
Recent news which mentions ASND
   Oppenheimer Maintains Outperform Rating for Ascendis Pharma: Here's What You Need To Know
   
  August 11, 2022
  Tickers 
   ASND
  
  
  From Benzinga
 From Benzinga
 From Benzinga
 From Benzinga
 
   12 Health Care Stocks Moving In Monday's Pre-Market Session
   
  
  
  March 14, 2022
  From Benzinga
 
   10 Biggest Price Target Changes For Monday
   
  
  
  March 14, 2022
  From Benzinga
 
   7 Biotech Stocks With Key Catalysts in March
   
  
  
  March 09, 2022
  From InvestorPlace
 From Benzinga
 
   Earnings Scheduled For March 2, 2022
   
  
  
  March 02, 2022
  From Benzinga
 From Benzinga
 
   Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2022
   
  
  
  February 14, 2022
  From Benzinga
 
   Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2022
   
  
  
  January 06, 2022
  From Benzinga
 
   Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021
   
  
  
  December 08, 2021
  From Benzinga
 
   The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial
   
  
  
  November 19, 2021
  From Benzinga
 
   Ascendis' Hypoparathyroidism Candidate Shows Durable Benefit At 84 Weeks
   
  November 19, 2021
  Tickers 
   ASND
  
  
  From Benzinga
 
   10 Biggest Price Target Changes For Monday
   
  
  
  November 15, 2021
  From Benzinga
 
   Ascendis Pharma A/S (ASND) Q3 2021 Earnings Call Transcript
   
  November 10, 2021
  Tickers 
   ASND
  
  
  From Motley Fool
 
   Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2021
   
  
  
  October 20, 2021
  From Benzinga
 
   This Growth Hormone Drug Could Be a Boost For Pfizer
   
  
  
  October 05, 2021
  From Motley Fool
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.